These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38108109)

  • 1. Effect of Anti-S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis-Specific Transcriptional Signatures in Human Skin.
    Trinh-Minh T; Györfi AH; Tomcik M; Tran-Manh C; Zhou X; Dickel N; Tümerdem BS; Kreuter A; Burmann SN; Borchert SV; Hussain RI; Hallén J; Klingelhöfer J; Kunz M; Distler JHW
    Arthritis Rheumatol; 2024 May; 76(5):783-795. PubMed ID: 38108109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin.
    Švec X; Štorkánová H; Trinh-Minh T; Tran MC; Štorkánová L; Hulejová H; Oreská S; Heřmánková B; Bečvář R; Pavelka K; Vencovský J; Klingelhöfer J; Hussain RI; Hallén J; Šenolt L; Distler JHW; Tomčík M
    Rheumatology (Oxford); 2024 Mar; 63(3):817-825. PubMed ID: 37314987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-S100A4 monoclonal antibody treatment ameliorates experimental skin fibrosis and SSc-specific transcriptional signatures in human skin: Comment on the targeting S100A4 is helpful in SSc treatment by Trinh-Minh et al.
    Huang AF; Xu WD
    Arthritis Rheumatol; 2024 Jul; 76(7):1164-1165. PubMed ID: 38351303
    [No Abstract]   [Full Text] [Related]  

  • 4. S100A4 amplifies TGF-β-induced fibroblast activation in systemic sclerosis.
    Tomcik M; Palumbo-Zerr K; Zerr P; Avouac J; Dees C; Sumova B; Distler A; Beyer C; Cerezo LA; Becvar R; Distler O; Grigorian M; Schett G; Senolt L; Distler JH
    Ann Rheum Dis; 2015 Sep; 74(9):1748-55. PubMed ID: 24709861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CX3CL1 (fractalkine) monoclonal antibody attenuates lung and skin fibrosis in sclerodermatous graft-versus-host disease mouse model.
    Hasegawa T; Utsunomiya A; Chino T; Kasamatsu H; Shimizu T; Matsushita T; Obara T; Ishii N; Ogasawara H; Ikeda W; Imai T; Oyama N; Hasegawa M
    Arthritis Res Ther; 2024 May; 26(1):94. PubMed ID: 38702742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.
    Manetti M; Romano E; Rosa I; Guiducci S; Bellando-Randone S; De Paulis A; Ibba-Manneschi L; Matucci-Cerinic M
    Ann Rheum Dis; 2017 May; 76(5):924-934. PubMed ID: 28062404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis.
    Zhang Y; Dees C; Beyer C; Lin NY; Distler A; Zerr P; Palumbo K; Susok L; Kreuter A; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2015 May; 74(5):936-43. PubMed ID: 24431397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX
    Luong VH; Utsunomiya A; Chino T; Doanh LH; Matsushita T; Obara T; Kuboi Y; Ishii N; Machinaga A; Ogasawara H; Ikeda W; Kawano T; Imai T; Oyama N; Hasegawa M
    Arthritis Rheumatol; 2019 Nov; 71(11):1923-1934. PubMed ID: 31173491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis.
    Grönberg C; Rattik S; Tran-Manh C; Zhou X; Rius Rigau A; Li YN; Györfi AH; Dickel N; Kunz M; Kreuter A; Matei EA; Zhu H; Skoog P; Liberg D; Distler JH; Trinh-Minh T
    Ann Rheum Dis; 2024 Aug; 83(9):1156-1168. PubMed ID: 38594058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
    Soare A; Györfi HA; Matei AE; Dees C; Rauber S; Wohlfahrt T; Chen CW; Ludolph I; Horch RE; Bäuerle T; von Hörsten S; Mihai C; Distler O; Ramming A; Schett G; Distler JHW
    Arthritis Rheumatol; 2020 Jan; 72(1):137-149. PubMed ID: 31350829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis.
    Desallais L; Avouac J; Fréchet M; Elhai M; Ratsimandresy R; Montes M; Mouhsine H; Do H; Zagury JF; Allanore Y
    Arthritis Res Ther; 2014 Jul; 16(4):R157. PubMed ID: 25059342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
    Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
    Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical role of the adhesion receptor DNAX accessory molecule-1 (DNAM-1) in the development of inflammation-driven dermal fibrosis in a mouse model of systemic sclerosis.
    Avouac J; Elhai M; Tomcik M; Ruiz B; Friese M; Piedavent M; Colonna M; Bernhardt G; Kahan A; Chiocchia G; Distler JH; Allanore Y
    Ann Rheum Dis; 2013 Jun; 72(6):1089-98. PubMed ID: 23161903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
    Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis.
    Mor A; Segal Salto M; Katav A; Barashi N; Edelshtein V; Manetti M; Levi Y; George J; Matucci-Cerinic M
    Ann Rheum Dis; 2019 Sep; 78(9):1260-1268. PubMed ID: 31129606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
    Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
    Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
    Huang J; Beyer C; Palumbo-Zerr K; Zhang Y; Ramming A; Distler A; Gelse K; Distler O; Schett G; Wollin L; Distler JH
    Ann Rheum Dis; 2016 May; 75(5):883-90. PubMed ID: 25858641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis.
    Ponsoye M; Frantz C; Ruzehaji N; Nicco C; Elhai M; Ruiz B; Cauvet A; Pezet S; Brandely ML; Batteux F; Allanore Y; Avouac J
    Ann Rheum Dis; 2016 Dec; 75(12):2142-2149. PubMed ID: 26912566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis.
    Wu M; Pedroza M; Lafyatis R; George AT; Mayes MD; Assassi S; Tan FK; Brenner MB; Agarwal SK
    Arthritis Rheumatol; 2014 Apr; 66(4):1010-21. PubMed ID: 24757152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.